<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18232">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01787110</url>
  </required_header>
  <id_info>
    <org_study_id>DETO2X-AMI 2012/287-12</org_study_id>
    <nct_id>NCT01787110</nct_id>
  </id_info>
  <brief_title>An Efficacy and Outcome Study of Supplemental Oxygen Treatment in Patients With Suspected Myocardial Infarction</brief_title>
  <acronym>DETO2X-AMI</acronym>
  <official_title>DETermination of the Role of OXygen in Suspected Acute Myocardial Infarction (DETO2X-AMI) Based on the SWEDEHEART Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swedish Heart Lung Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Foundation for Strategic Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Swedish Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of supplemental oxygen in the setting of suspected acute myocardial infarction (AMI)
      is manifested in international treatment guidelines and established in prehospital and
      hospital clinical routine throughout the world.

      However, to date there is no conclusive evidence from adequately designed and powered trials
      supporting this practice. Existing data is conflicting and failing to clarify the role of
      supplemental oxygen in AMI.

      The DETO2X-AMI trial is designed to shed light on this important issue.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AIM:

      The aim of the DETO2X-AMI trial is to evaluate the role of supplemental oxygen delivery in
      the setting of acute coronary syndrome myocardial infarction including ST-segment elevation
      myocardial infarction (STEMI), non ST-segment elevation myocardial infarction (NSTEMI) and
      unstable angina (UA).

      DESIGN:

      DETO2X-AMI is a multicentre, interventional, controlled, randomized registry based clinical
      trial (RRCT) recruiting 6600 patients at cardiac care facilities which report into the
      SWEDEHEART registry throughout the whole of Sweden.

      The SWEDEHEART (Swedish Web-system for Enhancement and Development of Evidence-based care in
      Heart disease Evaluated According to Recommended Therapies) registry is a nationwide used
      platform allowing a broad population of all-comers access to the broad registry network
      which includes:

        -  RIKS-HIA (nationwide registry where all ischemia cases treated on cardiac intensive
           care units are registered),

        -  SCAAR (Swedish Coronary Angiography and Angioplasty Registry where nationwide all
           coronary angiography and percutaneous coronary intervention (PCI) procedures are
           registered))

        -  SEPHIA (nationwide registry for all post AMI follow-up).

      All follow-up will be carried out in SWEDEHEART and other national registries such as the
      national death origin registry (dödsorsaksregister) or the in-patient care registry
      (slutenvårdsregister). A similar set-up has been successfully used for the TASTE (Thrombus
      Aspiration in ST-Elevation myocardial infarction in Scandinavia)trial.

      MATERIAL and METHODS:

      Patients with normal oxygen saturation (≥90% on pulse oximeter) presenting to the ambulance
      service or the emergency department (ED) with classical symptoms suggestive of acute
      coronary syndrome (ACS) and significant ECG changes or elevated cardiac biomarkers (ED) are
      evaluated for inclusion. If eligible, oral informed consent is obtained by EMD or ED
      personnel prior to inclusion. Randomization is carried out on the cardiac intensive care
      unit using a web-based tool as part of registration directly into the national SWEDEHEART
      registry.

      Patients are randomized to either supplemental oxygen delivered by oxymask® (6 L/min) for 12
      hours (min 6 hours) or no supplemental O₂. All patients receive standard care according to
      international ACS guidelines including acute coronary intervention.

      Primary endpoint is 1-year all-cause mortality. Secondary endpoints will furthermore
      evaluate mortality, complications during hospital stay, heart failure (echocardiography,
      registry), myocardial damage using cardiac resonance imaging (CMR), electrocardiogram,
      modern biomarkers and coronary angiography and health economics.

      Follow-up is carried out according to clinical post AMI routine which includes a
      standardized registration in the SWEDEHEART registry. Mortality data is obtained from the
      national death origin registry which is linked to SWEDEHEART.

      CONCLUSION:

      There is no conclusive evidence from adequately designed and powered trials supporting the
      routine administration of supplemental oxygen in the setting of suspected AMI. The
      DETO2X-AMI trial is designed to shed light on this important issue and give guidance to
      future recommendations.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>1-year all-cause mortality</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>1-year all-cause mortality on an intention to treat basis (ITT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial damage</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 3-5 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Myocardial damage assessed by cardiac resonance imaging (CMR), by electrocardiogram, biomarkers and coronary angiography using the index of microvascular resistance (IMR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality and morbidity</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 3-5 days, at 30 days and 1-year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate mortality during hospital stay, at 30 days and 1-year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure evaluation</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 3-5 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of the degree of heart failure by echocardiography, biomarkers and  number of patients needing medical (iv-drugs such as furosemide, nitroglycerine or inotropes) and/or mechanical (CPAP) assistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economics</measure>
    <time_frame>Health economics will be assessed from first contact with the ambulance service through to the duration of hospital stay, an expected average of 3-5 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Health economics concerning supplemental oxygen treatment from prehospital contact of the emergency service through to hospital discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6600</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Non-ST Elevation (NSTEMI) Myocardial Infarction</condition>
  <condition>Acute ST Segment Elevation Myocardial Infarction</condition>
  <condition>Angina, Unstable</condition>
  <arm_group>
    <arm_group_label>No oxygen</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>For patients randomised to withholding oxygen treatment
no oxygen is administered at any time as long as the oxygen saturation is ≥90% on pulse oximeter (repetitive checks are performed)
all patients receive standard acute coronary syndrome treatment including reperfusion strategies
observation duration 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxygen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For patients randomised to oxygen therapy:
6 L/min of oxygen delivered by oxymask® started immediately after inclusion of the ambulance service or in the emergency department given continuously for 6-12 hours (at least 6 hours)
all patients receive standard acute coronary syndrome treatment including reperfusion strategies</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>see arm description</description>
    <arm_group_label>Oxygen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  symptoms (chest pain, dyspnea) indicating acute myocardial ischemia within the last 6
             hours

          -  ECG changes (ST-segment elevation ≥ 2 mm V1-V4, or ≥ 1 mm in other leads, ST-segment
             depression &gt;1 mm in any lead, negative T-wave in leads V2-V6, pathological Q-wave in
             at least 2 adjacent leads), left bundle branch block

        and/or elevated levels of cardiac troponin levels in the ED

        indicating acute myocardial ischemia

          -  oxygen saturation ≥90% (pulse oximeter)

          -  age ≥30

        Exclusion Criteria:

          -  unwillingness to participate

          -  inability to comprehend given information

          -  continuous oxygen delivery at home prior to inclusion

          -  cardiac arrest prior to inclusion
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leif Svensson, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leif Svensson, MD, PHD</last_name>
    <phone>+4686161918</phone>
    <email>leif.svensson@sodersjukhuset.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robin Hofmann, MD</last_name>
    <phone>+4686162913</phone>
    <email>robin.hofmann@sodersjukhuset.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Enköping Hospital</name>
      <address>
        <city>Enköping</city>
        <zip>74525</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lena Forsman, MD</last_name>
      <email>lena.forsman@lul.se</email>
    </contact>
    <investigator>
      <last_name>Lena Forsman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gothenburg university Hospital, Östra Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Björn Hornestam, MD</last_name>
      <email>bjorn.hornestam@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Björn Hornestam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gothenburg University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Herlitz, MD, PHD</last_name>
      <email>johan.herlitz@gu.se</email>
    </contact>
    <investigator>
      <last_name>Johan Herlitz, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gävle Hospital</name>
      <address>
        <city>Gävle</city>
        <zip>80187</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Kastberg, MD</last_name>
      <email>robert.kastberg@lg.se</email>
    </contact>
    <investigator>
      <last_name>Lars Svennberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hallands Hospital Halmstad</name>
      <address>
        <city>Halmstad</city>
        <zip>30185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Markus Lingman, MD, PHD</last_name>
      <email>markus.lingman@regionhalland.se</email>
    </contact>
    <investigator>
      <last_name>Markus Lingman, MD,PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ryhov Hospital Jönköping</name>
      <address>
        <city>Jönköping</city>
        <zip>55185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan-Erik Karlsson, MD, PHD</last_name>
      <email>Jan-Erik.Karlsson@lj.se</email>
    </contact>
    <investigator>
      <last_name>Jan-Erik Karlsson, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kalmar Regional Hospital</name>
      <address>
        <city>Kalmar</city>
        <zip>39185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Carlsson, MD, PHD</last_name>
      <email>jorg.carlsson@ltkalmar.se</email>
    </contact>
    <investigator>
      <last_name>Jörg Carlsson, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karlstad Hospital</name>
      <address>
        <city>Karlstad</city>
        <zip>65185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urban Haaga, MD</last_name>
      <email>Urban.Haaga@liv.se</email>
    </contact>
    <investigator>
      <last_name>Urban Haaga, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kiruna Hospital</name>
      <address>
        <city>Kiruna</city>
        <zip>98131</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrik Kjellberg, MD</last_name>
      <email>Fredrik.Kjellberg@nll.se</email>
    </contact>
    <investigator>
      <last_name>Fredrik Kjellberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kristianstad Hospital</name>
      <address>
        <city>Kristianstad</city>
        <zip>29185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Pettersson, MD</last_name>
      <email>thomas.pettersson@skane.se</email>
    </contact>
    <investigator>
      <last_name>Thomas Pettersson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skaraborgs Hospital Lidköping</name>
      <address>
        <city>Lidköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Magnus Peterson, MD</last_name>
      <email>magnus.peterson@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Magnus Peterson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <zip>58191</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joakim Alfredsson, MD, PHD</last_name>
      <email>joakim.alfredsson@liu.se</email>
    </contact>
    <contact_backup>
      <last_name>Lennart Nilsson, MD, PHD</last_name>
      <email>lennart.nilsson@liu.se</email>
    </contact_backup>
    <investigator>
      <last_name>Lennart Nilsson, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital Lund</name>
      <address>
        <city>Lund</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulf Ekelund, MD, PHD</last_name>
      <email>ulf.ekelund@med.lu.se</email>
    </contact>
    <contact_backup>
      <last_name>David Erlinge, MD, PHD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Ulf Ekelund, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital Malmö</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Erlinge, MD, PHD</last_name>
      <email>david.erlinge@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ulf Ekelund, MD, PHD</last_name>
      <email>ulf.ekelund@med.lu.se</email>
    </contact_backup>
    <investigator>
      <last_name>David Erlinge, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vrinnevi Hospital Norrköping</name>
      <address>
        <city>Norrköping</city>
        <zip>60329</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christofer Digerfeldt, MD, PHD</last_name>
      <email>Christofer.Digerfeldt@lio.se</email>
    </contact>
    <investigator>
      <last_name>Lennart Nilsson, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norrtälje Hospital</name>
      <address>
        <city>Norrtälje</city>
        <zip>76129</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tommy Pettersson, MD</last_name>
      <email>tommy.pettersson@tiohundra.se</email>
    </contact>
    <investigator>
      <last_name>Tommy Pettersson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skaraborgs Hospital Skövde</name>
      <address>
        <city>Skövde</city>
        <zip>54185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Per Amandusson, MD</last_name>
      <email>per.amandusson@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Per Amandusson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St: Göran Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>11281</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Erlandsson, MD</last_name>
      <email>Marianne.Erlandsson@capiostgoran.se</email>
    </contact>
    <investigator>
      <last_name>Mattias Törnerud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Danderyds Sjukhus</name>
      <address>
        <city>Stockholm</city>
        <zip>18288</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rickard Linder, MD, PHD</last_name>
      <phone>+46812356122</phone>
      <email>rickard.linder@ds.se</email>
    </contact>
    <investigator>
      <last_name>Rickard Linder, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Pernow, MD, PHD</last_name>
      <email>john.pernow@ki.se</email>
    </contact>
    <investigator>
      <last_name>John Pernow, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Jernberg, MD, PHD</last_name>
      <email>tomas.jernberg@karolinska.se</email>
    </contact>
    <investigator>
      <last_name>Tomas Jernberg, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>11883</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Hofmann, MD, med dr</last_name>
      <phone>+4686162913</phone>
      <email>robin.hofmann@sodersjukhuset.se</email>
    </contact>
    <contact_backup>
      <last_name>Leif Svensson, MD, PHD</last_name>
      <phone>+4686161918</phone>
      <email>leif.svensson@sodersjukhuset.se</email>
    </contact_backup>
    <investigator>
      <last_name>Leif Svensson, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robin Hofmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Härnosand Hospital Sundsvall</name>
      <address>
        <city>Sundsvall</city>
        <zip>85186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Millbourn, MD</last_name>
      <email>anna.millbourn@lvn.se</email>
    </contact>
    <investigator>
      <last_name>Anna Millbourn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trelleborg Hospital</name>
      <address>
        <city>Trelleborg</city>
        <zip>23185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Troels Yndigegn, MD</last_name>
      <email>troels.yndigegn@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Troels Yndigegn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norrlands University Hospital</name>
      <address>
        <city>Umeå</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krister Lindmark, MD, PHD</last_name>
      <email>Krister.Lindmark@vll.se</email>
    </contact>
    <investigator>
      <last_name>Krister Lindmark, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan James, MD, PHD</last_name>
      <phone>+46705944404</phone>
      <email>stefan.james@ucr.uu.se</email>
    </contact>
    <investigator>
      <last_name>Stefan James, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hallands Hospital Varberg</name>
      <address>
        <city>Varberg</city>
        <zip>43281</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Markus Lingman, MD, PHD</last_name>
      <email>markus.lingman@regionhalland.se</email>
    </contact>
    <investigator>
      <last_name>Markus Lingman, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Växjö Hospital</name>
      <address>
        <city>Växjö</city>
        <zip>35188</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olle Bergström, MD</last_name>
      <email>olle.p.bergstrom@ltkronoberg.se</email>
    </contact>
    <investigator>
      <last_name>Olle Bergström, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ängelholm Hospital</name>
      <address>
        <city>Ängelholm</city>
        <zip>26281</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dragisa Barbulovic, MD</last_name>
      <email>dragisa.barbulovic@skane.se</email>
    </contact>
    <investigator>
      <last_name>Dragisa Barbulovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Kellerth, MD, PHD</last_name>
      <email>thomas.kellerth@orebroll.se</email>
    </contact>
    <investigator>
      <last_name>Thomas Kellerth, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.deto2x.se</url>
    <description>Click here for more information about this study</description>
  </link>
  <reference>
    <citation>Rawles JM, Kenmure AC. Controlled trial of oxygen in uncomplicated myocardial infarction. Br Med J. 1976 May 8;1(6018):1121-3.</citation>
    <PMID>773507</PMID>
  </reference>
  <reference>
    <citation>Farquhar H, Weatherall M, Wijesinghe M, Perrin K, Ranchord A, Simmonds M, Beasley R. Systematic review of studies of the effect of hyperoxia on coronary blood flow. Am Heart J. 2009 Sep;158(3):371-7. Epub 2009 Jul 15. Review.</citation>
    <PMID>19699859</PMID>
  </reference>
  <reference>
    <citation>Ranchord AM, Argyle R, Beynon R, Perrin K, Sharma V, Weatherall M, Simmonds M, Heatlie G, Brooks N, Beasley R. High-concentration versus titrated oxygen therapy in ST-elevation myocardial infarction: a pilot randomized controlled trial. Am Heart J. 2012 Feb;163(2):168-75. doi: 10.1016/j.ahj.2011.10.013. Epub 2012 Jan 13.</citation>
    <PMID>22305833</PMID>
  </reference>
  <reference>
    <citation>Ukholkina GB, Kostianov IIu, Kuchkina NV, Grendo EP, Gofman IaB. [Effect of oxygenotherapy used in combination with reperfusion in patients with acute myocardial infarction]. Kardiologiia. 2005;45(5):59. Russian.</citation>
    <PMID>16007057</PMID>
  </reference>
  <reference>
    <citation>Moradkhan R, Sinoway LI. Revisiting the role of oxygen therapy in cardiac patients. J Am Coll Cardiol. 2010 Sep 21;56(13):1013-6. doi: 10.1016/j.jacc.2010.04.052.</citation>
    <PMID>20846598</PMID>
  </reference>
  <reference>
    <citation>Cabello JB, Burls A, Emparanza JI, Bayliss S, Quinn T. Oxygen therapy for acute myocardial infarction. Cochrane Database Syst Rev. 2010 Jun 16;(6):CD007160. doi: 10.1002/14651858.CD007160.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;8:CD007160.</citation>
    <PMID>20556775</PMID>
  </reference>
  <reference>
    <citation>Burls A, Cabello JB, Emparanza JI, Bayliss S, Quinn T. Oxygen therapy for acute myocardial infarction: a systematic review and meta-analysis. Emerg Med J. 2011 Nov;28(11):917-23. doi: 10.1136/emj.2010.103564. Epub 2011 Feb 23. Review.</citation>
    <PMID>21346260</PMID>
  </reference>
  <reference>
    <citation>Fröbert O, Lagerqvist B, Gudnason T, Thuesen L, Svensson R, Olivecrona GK, James SK. Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia (TASTE trial). A multicenter, prospective, randomized, controlled clinical registry trial based on the Swedish angiography and angioplasty registry (SCAAR) platform. Study design and rationale. Am Heart J. 2010 Dec;160(6):1042-8.</citation>
    <PMID>21146656</PMID>
  </reference>
  <reference>
    <citation>Kones R. Oxygen therapy for acute myocardial infarction-then and now. A century of uncertainty. Am J Med. 2011 Nov;124(11):1000-5. doi: 10.1016/j.amjmed.2011.04.034. Review.</citation>
    <PMID>22017777</PMID>
  </reference>
  <reference>
    <citation>Shuvy M, Atar D, Gabriel Steg P, Halvorsen S, Jolly S, Yusuf S, Lotan C. Oxygen therapy in acute coronary syndrome: are the benefits worth the risk? Eur Heart J. 2013 Jun;34(22):1630-5. doi: 10.1093/eurheartj/eht110. Epub 2013 Apr 3.</citation>
    <PMID>23554440</PMID>
  </reference>
  <reference>
    <citation>Stub D, Smith K, Bernard S, Bray JE, Stephenson M, Cameron P, Meredith I, Kaye DM; AVOID Study. A randomized controlled trial of oxygen therapy in acute myocardial infarction Air Verses Oxygen In myocarDial infarction study (AVOID Study). Am Heart J. 2012 Mar;163(3):339-345.e1. doi: 10.1016/j.ahj.2011.11.011.</citation>
    <PMID>22424003</PMID>
  </reference>
  <reference>
    <citation>Hofmann R, James SK, Svensson L, Witt N, Frick M, Lindahl B, Östlund O, Ekelund U, Erlinge D, Herlitz J, Jernberg T. DETermination of the role of OXygen in suspected Acute Myocardial Infarction trial. Am Heart J. 2014 Mar;167(3):322-8. doi: 10.1016/j.ahj.2013.09.022. Epub 2013 Dec 19.</citation>
    <PMID>24576515</PMID>
  </reference>
  <reference>
    <citation>Fröbert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, Aasa M, Angerås O, Calais F, Danielewicz M, Erlinge D, Hellsten L, Jensen U, Johansson AC, Kåregren A, Nilsson J, Robertson L, Sandhall L, Sjögren I, Ostlund O, Harnek J, James SK. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med. 2013 Oct 24;369(17):1587-97. doi: 10.1056/NEJMoa1308789. Epub 2013 Aug 31.</citation>
    <PMID>23991656</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 27, 2014</lastchanged_date>
  <firstreceived_date>February 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Leif Svensson</investigator_full_name>
    <investigator_title>Professor of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Acute coronary syndrome</keyword>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>Non ST-segment Myocardial Infarction</keyword>
  <keyword>ST-segment Myocardial Infarction</keyword>
  <keyword>STEMI</keyword>
  <keyword>NSTEMI</keyword>
  <keyword>Oxygen</keyword>
  <keyword>Unstable angina</keyword>
  <keyword>Randomised trial</keyword>
  <keyword>CMR</keyword>
  <keyword>Mortality</keyword>
  <keyword>RCRT</keyword>
  <keyword>RRCT</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
